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Abstract 
Background: Topical photodynamic therapy is an established treatment modality for various 
dermatological conditions, including actinic keratosis. In Europe, the approved protocols for 
photodynamic therapy of actinic keratosis involve irradiation with either an Aktilite CL 128 
lamp or daylight, whereas irradiation with the Blu-U illuminator is approved in the United 
States. Many other protocols using irradiation by a variety of light sources are also clinically 
efficient. 
Objectives: This paper aims to compare ten different protocols with clinically proven efficacy 
for photodynamic therapy of actinic keratosis and the available spectral irradiance of the light 
source. Effective irradiance, effective light dose and local damage are compared. We also 
investigate whether there is an association between the complete response rate at three months 
and the effective light dose or local damage. 
Methods: The effective irradiance, also referred to as protoporphyrin IX-weighted irradiance, 
is obtained by integrating the spectral irradiance weighted by the normalized absorption 
spectrum of protoporphyrin IX over the wavelength. Integrating the effective irradiance over 
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the irradiation time yields the effective light dose, which is also known as the protoporphyrin 
IX-weighted light dose. Local damage, defined as the total cumulative singlet oxygen 
molecules produced during treatment, is estimated using mathematical modeling of the 
photodynamic therapy process. This modeling is based on an iterative procedure taking into 
account the spatial and temporal variations in the protoporphyrin IX absorption spectrum 
during treatment. 
Results: The protocol for daylight photodynamic therapy on a clear sunny day, the protocol 
for daylight photodynamic therapy on an overcast day, the photodynamic therapy protocol for 
a white LED lamp for operating rooms and the photodynamic therapy protocol for the Blu-U 
illuminator perform better than the six other protocols ─ all involving red light illumination ─ 
in terms of both effective light dose and local damage. However, no association between the 
complete response rate at three months and the effective light dose or local damage was 
found. 
Conclusions: Protocols that achieve high complete response rates at three months and low 
pain scores should be preferred regardless of the effective light dose and local damage. 
 
Keywords: Photodynamic therapy, actinic keratosis, protocols with clinically proven 
efficacy, protocols with available spectral irradiance for the light source, effective 
irradiance, effective light dose, local damage, complete response rate at three months. 
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I. Introduction 
 
Photodynamic therapy (PDT), which is an established modality for the treatment of a variety 
of skin conditions, including skin cancers, combines the use of a light of an appropriate 
wavelength, a nontoxic photosensitizer, and sufficient molecular oxygen to generate reactive 
oxygen species and destroy target cells [1]. Over the last 15 years, PDT using 5-
aminolevulinic acid (ALA) (ALA-PDT) and PDT using 5-aminolevulinic acid methyl ester 
(MAL) (MAL-PDT) have been extensively investigated, particularly for the treatment of 
actinic keratosis (AK) [2-6]. Topical administration of ALA or MAL leads, after the 
incubation time, to the selective accumulation of the endogenous photosensitizer 
protoporphyrin IX (PpIX) in the AK cells, and subsequent light irradiation induces 
photochemical reactions leading to cell death. 
 
A variety of ALA- and MAL-PDT protocols have been proposed for the treatment of AK [2-
6]. In this paper, we propose a comparison of ten different ALA- and MAL-PDT protocols 
with clinically proven efficacy for PDT of AK and available spectral data for the light source. 
The comparison is performed in terms of effective irradiance, effective light dose and local 
damage. The effective irradiance, also referred to as the PpIX-weighted irradiance, is obtained 
by integrating the spectral irradiance of the light source weighted (i.e., multiplied for each 
wavelength) by the normalized absorption spectrum of PpIX over the wavelength. Integrating 
this effective irradiance over the irradiation time gives the effective light dose, also known as 
the PpIX-weighted light dose. Local damage, which is defined as the estimate of the total 
cumulative singlet oxygen molecules produced during treatment, is computed by 
mathematical modeling of PDT of AK, which we have published previously [7-9]. Based on 
an iterative procedure, this modeling takes into account the spatial and temporal variations in 
the absorption spectrum of PpIX during treatment. 
 
Furthermore, the complete response rates at three months, which are reported in the literature 
for nine of the ten investigated protocols, are compared to the effective light doses and local 
damage. This comparison aims to investigate whether there is an association between the 
complete response rate at three months and the effective light dose or local damage. 
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The ten ALA- and MAL-PDT protocols investigated in this study are described in the 
Materials and Methods section. This section also includes a description of the three 
comparative metrics. The protocols are then evaluated and compared in the Results section, 
which also addresses the relationships of the complete response rate at three months with the 
effective light dose and with local damage. Finally, some discussions and conclusions are 
drawn in the Discussion section. 
 
II. Materials and Methods 
 
A. ALA- and MAL-PDT protocols for AK treatment 
 
Ten different ALA- and MAL-PDT protocols are investigated in this study. For each protocol, 
a description specifying the incubation time, light source, irradiation time, removal of excess 
cream, and any potential additional protocol information is given. All protocol information 
was collected from the studies establishing the clinical efficacy of the protocols. 
 
The order in which the protocols appear is determined by the technology of the involved light 
sources. 
 
Table 1 summarizes the abovementioned information for the ten ALA- and MAL-PDT 
protocols investigated in this study (columns 2 to 6) as well as the complete response rates at 
three months (column 7) and the pain scores during irradiation (column 8). Only the complete 
response rates and the pain scores achieved in AK after one PDT session are considered in 
this study. 
 
1. Daylight 
 
Since the early work of Wiegell et al. 2008 [10], many studies on daylight PDT for the 
treatment of AK have been published [6,11-22]. Application of a chemical sunscreen to the 
treatment area to prevent sunburn, followed by a maximum of 30 minutes of MAL incubation 
and no excess cream removal before exposure to daylight for two hours, was adopted as the 
so-called international consensus protocol for daylight PDT from a European consensus in 
2012 [13]. In our study, we investigated the performance of the international consensus 
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protocol for daylight PDT for an incubation time of 30 minutes. This choice was based on a 
randomized clinical trial that demonstrated that this protocol is as effective as but less painful 
than the conventional protocol for Aktilite CL 128 PDT (described in Paragraph II.A.2.a.iii, 
the conventional protocol for Aktilite CL 128 PDT is commonly used for standard PDT of 
AK in Europe) [16]. Moreover, as this randomized clinical trial was conducted under all 
weather conditions except rain and cold, two spectral irradiances for daylight are used in this 
study. The first corresponds to a clear sunny day at 10h28 (orange yellow curve in Figure 1) 
and thus is used to set the protocol for daylight PDT on a clear sunny day, whereas the second 
corresponds to an overcast day at 13h45 (dark gray curve in Figure 1) and defines the protocol 
for daylight PDT on an overcast day. The two spectral irradiances recorded between April and 
July 2014 in Dublin, Ireland, were kindly provided by the authors of O’Gorman et al. [21]. 
 
2. Artificial light sources 
 
a) Incoherent light sources 
 
Three main technologies for turning electricity into incoherent light ─ incandescent bulbs, gas 
discharge lamps and light-emitting diodes ─ have been investigated as light sources for PDT. 
 
i. Incandescent light bulb 
 
Since the advent of PDT for dermatology, incandescent bulbs, particularly halogen bulbs, 
have been employed as light sources. In this study, we have investigated a protocol for the 
broadband halogen CureLight 01 lamp (Photocure ASA, Oslo, Norway). This protocol 
involves a three-hour MAL incubation followed by removal of excess cream before 
irradiation with a light dose of 75 J/cm
2
 and has been proven clinically effective for AK, 
based on reported complete response rates at three months of 68.7 to 91% (after one or two 
treatment sessions) [23-26]. The spectral irradiance for the CureLight 01 lamp used in this 
study is depicted in Figure 1 (maroon curve). This spectral irradiance is obtained by weighting 
the CureLight 01 lamp spectral irradiance provided in relative units by the authors of [27] to 
yield an irradiance of 154 mW/cm
2
. With this irradiance, which is the mean irradiance 
measured for the CureLight 01 lamp in [23], the above light dose of 75 J/cm
2
 is achieved 
using an irradiation time of 487 seconds. 
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ii. Gas discharge lamp 
 
Gas-discharge lamps include many categories, such as metal halide lamps, xenon arc lamps, 
fluorescent lamps, mercury lamps, and sodium lamps. In this study, we investigate two 
protocols involving irradiation with commercial gas discharge lamps. 
The first protocol is the manufacturer-recommended protocol for the Waldmann PDT 1200L 
(Waldmann Medizintechnik, VS-Schwennigen, Germany) [28], which is a metal halide lamp 
widely investigated for PDT of AK [28-35]. This protocol, which involves an incubation for 
four hours with ALA cream and removal of excess cream before irradiation at 160 mW/cm
2
 
for 625 seconds (the irradiation time required to achieve the recommended light dose of 100 
J/cm
2
), has been demonstrated to be clinically effective for ALA-PDT of AK [28]. The 
spectral irradiance used in this study for the Waldmann PDT 1200L was derived by weighting 
the relative spectral irradiance provided by the manufacturer to obtain an irradiance of 160 
mW/cm
2
. This spectral irradiance is depicted in sienna in Figure 1. 
The second protocol, which is the most commonly used approved protocol in the United 
States, involves irradiation with the widely available Blu-U illuminator (DUSA, Wilmington, 
Massachusetts, USA) [36-39]. The Blu-U protocol, which involves an ALA incubation time 
of 14 hours (within a recommended range of 14 to 18 hours) and excess cream removal before 
irradiation with a light dose of 10 J/cm
2
 administered in 1000 s (resulting in an irradiance of 
10 mW/cm
2
), has been demonstrated to be an effective therapy for PDT of AK in various 
clinical studies [36-39]. The spectral irradiance for the Blu-U that we use to evaluate this 
protocol is shown in blue in Figure 1. This spectral irradiance is computed by weighting the 
spectral irradiance extracted from some DUSA Pharmaceuticals files (See: 
https://www.physiciansofficeresource.com/por-resources/pdf/2099-8132-learn-more.pdf) to 
achieve an irradiance of 10 mW/cm
2
. 
 
iii. LED lamp 
 
In early 2000, developments in LED technology enabled the introduction of LED lamps as 
light sources in dermatological PDT. In this study, four protocols involving irradiation with 
LED lamps are evaluated. The first three are commercial solutions for dermatological PDT. 
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The first protocol involves irradiation with an Aktilite CL 128 lamp (Galderma SA, Lausanne, 
Switzerland), which is the most widely used LED lamp for topical PDT in Europe [16,26,40-
46]. In this paper, we evaluate the so-called conventional protocol for Aktilite CL 128 PDT 
(incubation with MAL cream: three hours; excess cream removal; light dose: 37 J/cm
2
). This 
protocol, which is clinically proven to be effective for the treatment of AK [10,16,40-44], is 
approved and widely used in Europe. To evaluate this protocol, we use the spectral irradiance 
measured at a distance of 8 cm from the Aktilite CL 128 lamp by O’Gorman et al. [21] (dark 
orange curve in Figure 1). 
The second protocol is the manufacturer-recommended protocol for the Omnilux PDT ™ 
(Photo Therapeutics Inc., Carlsbad, California) [28]. This protocol, which has been proven 
clinically efficient for PDT of AK [28], involves a four-hour ALA incubation, excess cream 
removal, and irradiation with a light dose of 40 J/cm
2
 [28]. The spectral irradiance used in this 
paper (orange red curve in Figure 1) was recorded at 3.5 cm from the front of the Omnilux 
PDT ™ by O’Gorman et al. [21]. 
The third protocol employs the Ambulight PDT ™ device developed by Ambicare Health Ltd 
(St Andrews, UK) as the light source [47-49]. This protocol, which has been reported to be 
efficient with similar 1-year clearance rates as the conventional protocol for Aktilite CL 128 
PDT [49], has the following characteristics: three hours of incubation with MAL, no excess 
cream removal, and 75 J/cm
2
 irradiation at an irradiance of 7 mW/cm
2
. The spectral irradiance 
for the Ambulight PDT ™ that we use to evaluate this protocol is extracted from [49] (salmon 
curve in Figure 1). 
The fourth protocol involves irradiation with a white LED lamp for operating rooms [21]. 
Replacing daylight irradiation with irradiation with this white LED lamp in the international 
consensus protocol for daylight PDT has been proven to achieve similar efficiency [21]. Note 
that the resulting protocol (incubation with MAL cream: 30 minutes; no excess cream 
removal; irradiation: two hours) does not require the application of a chemical sunscreen. The 
spectral irradiance for the white LED lamp for operating rooms provided by O’Gorman et al 
[21] is represented in light gray in Figure 1. 
 
b) Coherent light sources 
 
i. Laser 
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Various studies report the use of lasers as a light source for PDT of AK. In this study, only 
one protocol involving irradiation with a laser is investigated. This protocol, which includes 
incubation for 30 minutes with MAL cream and no excess cream removal, involves 
fractionated irradiation (6.7 milliseconds light, 13.4 milliseconds dark) with an irradiance of 4 
mW/cm
2
 for 9000 seconds, resulting in a light dose of 12 J/cm
2
 [50]. Based on the 
preliminary results of a clinical trial with Principal Investigator Pr. Laurent Mortier, one of 
the authors of this study (ClinicalTrials.gov Identifier: NCT03076892) 
(http://www.phosistos.com/), this protocol, which is called the PDT protocol for the PHOS-
ISTOS device, has been proven to be not inferior in terms of the complete response rate to the 
conventional protocol for Aktilite CL 128 PDT [51,52]. The spectral irradiance that we 
measured for the PHOS-ISTOS device is shown in red in Figure 1. 
 
B. Comparative metrics 
 
For each of the protocols investigated in this study, several metrics are computed from the 
protocol information: 
 The irradiance, which is obtained by integration over the wavelength of the spectral 
irradiance; 
 The light dose, which is the irradiance integrated over the irradiation time; 
 The effective irradiance, which is obtained by integration over the wavelength of the 
spectral irradiance weighted by the normalized absorption spectrum of PpIX; 
 The effective light dose, which is the effective irradiance integrated over the irradiation 
time; 
 The local damage, which is an estimate of the number of singlet oxygen molecules 
generated during treatment in a 5 µm × 5 µm × 5 µm volume located at a depth of 100 µm 
in AK. 
 
The irradiance and the light dose, which are sometimes specified when defining the protocol 
(Table 1), only allow the quantification of the electromagnetic radiation emitted by the 
involved light source without any consideration of the protocol other than the spectral 
irradiance and the irradiation time. Regarding the effective irradiance and the effective light 
dose, an additional consideration for the protocol is the normalized absorption spectrum of 
PpIX; this is achieved by weighting the spectral irradiance by the normalized absorption 
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spectrum of PpIX before integration over the wavelength. This weighting takes into account 
the varying efficiency of the light source in photoactivating PpIX depending on the 
wavelength: the higher the PpIX absorption coefficient, the greater the number of photons 
absorbed and therefore the greater the number of PpIX molecules promoted to the excited 
state. The effective irradiance therefore indicates the overall efficiency of the protocol for 
photoactivating PpIX, whereas the effective light dose represents the accumulation of this 
overall efficiency over the irradiation time. As the damage induced by PDT depends on the 
amount of singlet oxygen generated per unit volume of tissue during treatment [53,54], local 
damage appears to be a suitable metric for protocol assessment. Defined as the integration of 
a function of both the spectral irradiance and the absorption spectrum of PpIX over the 
irradiation time [7-9], the local damage is computed by mathematical modeling for PDT of 
AK. This modeling takes into account the spatial and temporal variations in the absorption 
spectrum of PpIX during treatment: the absorption spectrum of PpIX is initialized depending 
on the incubation time and then changes in space and time along the irradiation time 
according to the biological clearance of PpIX, the conversion of MAL to PpIX and the 
photobleaching of PpIX. All protocol information is integrated in the local damage 
computation. 
 
All five metrics are computed using a Matlab™ program on a standard personal computer 
(Intel Xeon CPU E5-2660 V3 – 2.60 GHz – 64 GB of RAM – Windows 7 64 bits). Based on 
their greater relevance for evaluating protocols for PDT of AK, only the effective irradiance, 
the effective light dose and the local damage are used as comparative metrics. Both the 
effective light dose and the local damage are quantities that accumulate over the irradiation 
time and could therefore be predictors of clinical outcome. For this reason, we also investigate 
whether there is an association between the clinical outcome ─ which is available in terms of 
the complete response rate at three months for nine of the ten protocols ─ and the effective 
light dose or local damage. 
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Table 1: The ten ALA- and MAL-PDT protocols investigated in this study: characteristics (columns 2 to 6), complete response rates at three 
months (column 7) and pain scores during irradiation (column 8). Both the complete response rates at three months and pain scores during 
irradiation considered in this study are derived from the literature and were achieved in AK after one PDT session. 
 
Incubation time 
(Photosensitizing 
cream) 
Should the excess 
photosensitizing 
cream be removed 
(Any potential 
additional 
information) 
Irradiation 
time 
Irradiance 
Light 
dose 
AK complete response 
rates at three months 
Pain scores 
ranging from 0 
(no pain) to 10 
(maximum 
pain) 
Protocol for 
daylight PDT on 
a clear sunny 
day 
[13,16,18,21] 
30 minutes (MAL) 
No (Application of a 
chemical sunscreen) 
2 hours 
(7200 
seconds) 
  
Including all weather 
conditions except rain or 
cold: 
 74% (This percentage 
is related to grade I 
AK, for which only 
one PDT session was 
performed) [18] 
 52.3% [21] 
 85.3% [16] 
Including all 
weather 
conditions 
except rain or 
cold: 
 1.9 [18] 
 0.4 [21] 
 0.8 [16] 
Protocol for 
daylight PDT on 
an overcast day 
[13,16,18,21] 
  
PDT protocol for 3 hours (MAL) Yes 487 154 75  68% (This  
11 
 
the CureLight 01 
lamp [23-26] 
seconds mW/cm
2
 
[23] 
J/cm
2
 percentage is 
related to facial 
and scalp AK, for 
which only one 
PDT session was 
performed) [26] 
PDT protocol for 
the Waldmann 
PDT 1200L [28] 
4 hours (ALA) Yes 
625 
seconds 
160 
mW/cm
2
 
100 
J/cm
2
 
 53.8% [28]  6.8 [28] 
PDT protocol for 
the Blu-U 
illuminator [36-
39] 
14 hours (ALA) Yes 
1000 
seconds 
10 
mW/cm
2
 
10 
J/cm
2
 
 86% [39]  
Conventional 
protocol for 
Aktilite CL 128 
PDT [10,16,40-
44] 
3 hours (MAL) Yes 
~433.3 
seconds 
 
37 
J/cm
2
 
 61.4% [44] 
 86.9% [41] 
 88.9% [16] 
 71.1% [10] 
 6.47 [44] 
 5.2 [41] 
 5.7 [16] 
 6.7 [10] 
Protocol for the 
Omnilux PDT ™ 
[28] 
4 hours (ALA) Yes 
~672.2 
seconds 
 
40 
J/cm
2
 
 55.8% [28]  6.95 [28] 
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Protocol for the 
Ambulight PDT 
™ [49] 
3 hours (MAL) No 
~3 hours 
(~10714.3 
seconds) 
7 
mW/cm
2
 
75 
J/cm
2
 
  
PDT protocol for 
a white LED 
lamp for 
operating rooms 
[21] 
30 minutes (MAL) No 
2 hours 
(7200 
seconds) 
   58% [21]  0.6 [21] 
PDT protocol for 
the PHOS-
ISTOS device 
[50] 
30 minutes (MAL) No 
2.5 hours 
(9000 
seconds) 
4 
mW/cm
2
 
12 
J/cm
2
 
 65.8% 
(Preliminary 
results) [51,52] 
 0.7 
(Preliminary 
results) 
[51,52] 
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Figure 1: The spectral irradiances for the ten ALA- and MAL-PDT protocols investigated in 
this study are scaled according to the left axis; the normalized absorption spectrum for PpIX 
(green curve) is plotted according to the right axis. 
 
III. Results 
 
Figure 2 allows a comparison of the ten ALA- and MAL-PDT protocols investigated in this 
study in terms of effective irradiance, effective light dose and local damage, all the three 
computed from the protocols information reported in Table 1 and Figure 1. 
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Table 2: Effective irradiances, effective light doses, local damage and other quantitative criteria computed from the spectral irradiances for the 
ten ALA- and MAL-PDT protocols investigated in this study. 
 
Irradiance 
(mW/cm
2
) 
Effective irradiance 
(mW/cm
2
) 
Light dose 
(J/cm
2
) 
Effective light 
dose 
(J/cm
2
) 
Local damage 
(AU) 
Protocol for daylight PDT on a 
clear sunny day [13,16,18,21] 
55.2 5.08 397.44 36.56 4425010.95 
Protocol for daylight PDT on an 
overcast day [13,16,18,21] 
7.75 0.79 55.82 5.72 1205257.88 
PDT protocol for the CureLight 
01 lamp [23-26] 
154 1.33 75 0.65 669417.46 
PDT protocol for the Waldmann 
PDT 1200L [28] 
160 0.93 100 0.58 832499.07 
PDT protocol for the Blu-U 
illuminator [36-39] 
10 4.1 10 4.1 2166724.45 
Conventional protocol for 
Aktilite CL 128 PDT [10,16,40-
44] 
85.39 1.44 37 0.63 680669.91 
Protocol for the Omnilux PDT ™ 59.51 0.95 40 0.64 898973.57 
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[28] 
Protocol for the Ambulight PDT 
™ [49] 
7 0.12 75 1.32 1624394.41 
PDT protocol for a white LED 
lamp for operating rooms [21] 
56.05 1.35 403.58 9.73 2340142.99 
PDT protocol for the PHOS-
ISTOS device [50] 
4 0.06 12 0.18 117498.17 
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Figure 2: Representation of the effective irradiances (blue bars), effective light doses (green bars) and local damage (red bars) for the ten ALA- 
and MAL-PDT protocols investigated in this study. For each protocol, the average complete response rate at three months, computed from the 
values reported in column 7 in Table 1, is specified in the text box above the bars related to the protocol. 
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Table 2 (column 3) and Figure 2 (blue bars) indicate a wide range of effective irradiances, 
from 0.06 mW/cm
2
 for the PDT protocol for the PHOS-ISTOS device to 5.08 mW/cm
2
 for the 
protocol for daylight PDT on a clear sunny day. This wide range results from the variations in 
position, shape and amplitude of the spectral irradiances with regard to the normalized 
absorption spectrum for PpIX (Figure 1). 
With a spectral irradiance completely overlapping the normalized absorption spectrum of 
PpIX and an irradiance of 55.2 mW/cm
2
, the protocol for daylight PDT on a clear sunny day 
provides the highest effective irradiance and therefore is the most efficient protocol for 
photoactivating PpIX. The protocol for daylight PDT on an overcast day, which involves a 
spectral irradiance with substantially the same broadband shape but an amplitude 
approximately seven times lower than that of the protocol for daylight PDT on a clear sunny 
day, is the eighth most efficient protocol for photoactivating PpIX. In spite of a partial overlap 
of the spectral irradiance with the first peak in the normalized absorption spectrum for PpIX, 
which is the most effective peak for photoactivation of PpIX (wavelength range of 300 nm to 
460 nm in Figure 1), the PDT protocol for the Blu-U illuminator only provides the second 
highest effective irradiance. This result occurs because the irradiance of 10 mW/cm
2
 for the 
PDT protocol for the Blu-U illuminator is more than five times lower than that for the 
protocol for daylight PDT on a clear sunny day. Although large differences exist in their 
spectral irradiances (Figure 1), the conventional protocol for Aktilite CL 128 PDT, the PDT 
protocol for a white LED lamp for operating rooms and the PDT protocol for the CureLight 
01 lamp provide quite similar effective irradiances, ranked as the third, fourth and fifth 
highest effective irradiance, respectively. The ranks of the conventional protocol for Aktilite 
CL 128 PDT and the PDT protocol for the CureLight 01 result from the high irradiances of 
85.39 mW/cm
2
 and 154 mW/cm
2
, which partially offset the overlap of the spectral irradiances 
with the two least effective peaks for photoactivation of PpIX in the normalized absorption 
spectrum for PpIX. The fourth rank of the PDT protocol for a white LED lamp for operating 
rooms is based on the combination of a suitable irradiance and the complete overlap of the 
spectral irradiance with the normalized absorption spectrum of PpIX. With substantially the 
same shape but an amplitude lower than that for the conventional protocol for Aktilite CL 128 
PDT, the spectral irradiance for the protocol for the Omnilux PDT ™ leads to the sixth 
highest effective irradiance. The irradiance of the PDT protocol for the Waldmann PDT 
1200L, although the highest in this study, does not compensate for the approximately 50% of 
the spectral irradiance that matches the wavelength range of 650 nm to 800 nm and therefore 
does not contribute to the photoactivation of PpIX. This non-contribution, which might 
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introduce unwanted heating of the tissue by infrared absorption and which is also observed for 
the PDT protocol for the CureLight 01 lamp, is clearly identifiable in Figure 1. With the two 
lowest irradiances in this study and an overlap of their spectral irradiances with the fifth 
absorption peak in the normalized absorption spectrum for PpIX, the protocol for the 
Ambulight PDT ™ and the PDT protocol for the PHOS-ISTOS device are the two least 
efficient protocols for photoactivating PpIX. 
 
The effective light dose, which is computed by integrating the effective irradiance over the 
irradiation time (column 4 in Table 1), also varies considerably in amplitude (column 5 in 
Table 2, green bars in Figure 2). 
With the highest effective irradiance (previous paragraph) and one of the longest irradiation 
times, the protocol for daylight PDT on a clear sunny day provides the highest effective light 
dose (value, 36.56 J/cm
2
). The PDT protocol for a white LED lamp for operating rooms has 
the second highest effective light dose due to the combination of the fourth highest effective 
irradiance with the third longest irradiation time. The protocol for daylight PDT on an 
overcast day and the PDT protocol for the Blu-U illuminator provide the third and fourth 
highest effective light doses, respectively. With the longest irradiation time in this study, the 
protocol for the Ambulight PDT ™ moves from ninth place in terms of effective irradiance to 
fifth place in terms of effective light dose. By contrast, the PDT protocol for the CureLight 01 
lamp, the PDT protocol for the Waldmann PDT 1200L, the conventional protocol for Aktilite 
CL 128 PDT and the protocol for the Omnilux PDT ™, which have the shortest irradiation 
times in this study, are lower ranked in terms of effective light dose than in terms of effective 
irradiance. For the PDT protocol for the PHOS-ISTOS device, the irradiation time of 2.5 
hours ─ the second highest irradiation time in this study (column 4 in Table 1) ─ does not 
result in better performance in terms of effective light dose (last rank with a value of 0.18 
J/cm
2
) than in terms of effective irradiance. Based on the results reported in columns 4 and 6 
of Table 2, all protocols with an irradiation time strictly less than two hours perform lower in 
terms of effective light dose than in terms of effective irradiance, whereas the other protocols 
are better or equally ranked in effective light dose compared to effective irradiance. 
 
With respect to local damage (red bars in Figure 2), which is computed by taking into account 
the time and depth variations of the absorption spectrum for PpIX along the PDT process, the 
protocol for daylight PDT on a clear sunny day is the most effective protocol in this study. 
The PDT protocol for a white LED lamp for operating rooms takes second place, followed 
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closely by the PDT protocol for the Blu-U illuminator. These results are mainly due to the 
relevant overlaps of the corresponding spectral irradiances with the normalized absorption 
spectrum of PpIX. Due to their long irradiation times, the protocol for the Ambulight PDT ™ 
and the protocol for daylight PDT on an overcast day provide the fourth and fifth highest local 
damage, respectively. Next, the PDT protocol for the CureLight 01 lamp, the PDT protocol 
for the Waldmann PDT 1200L, the conventional protocol for Aktilite CL 128 PDT and the 
protocol for the Omnilux PDT ™ achieve relatively similar levels of local damage, while the 
lowest local damage is achieved by the PDT protocol for the PHOS-ISTOS device. 
 
The rankings of the protocol for daylight PDT on a clear sunny day, the conventional protocol 
for Aktilite CL 128 PDT, the PDT protocol for a white LED lamp for operating rooms and the 
PDT protocol for the PHOS-ISTOS device based on local damage are identical to those based 
on effective light dose. For the other protocols, the rankings in terms of local damage are only 
slightly different from that based on effective light dose. These differences are partly due to 
the implicit consideration of the incubation time in the local damage calculation, i.e., the 
initialization of the absorption spectrum of PpIX depending on the incubation time. As a 
result, six of the seven protocols involving an incubation time less than or equal to three hours 
are equally or lower ranked in local damage than in effective light dose, whereas the three 
protocols involving an incubation time longer than four hours perform better in terms of local 
damage than in terms of effective light dose. 
 
As shown in Figure 2, the average complete response rate at three months (text boxes) does 
not appear to depend on either the effective light dose or the local damage. With the two 
highest effective light doses and the two highest local damages, the protocol for daylight PDT 
on a clear sunny day and the PDT protocol for a white LED lamp for operating rooms achieve 
average complete response rates at three months of 70.5% and 58%, respectively. These 
values are smaller than those achieved using the PDT protocol for the Blu-U illuminator 
(86%) and the conventional protocol for Aktilite CL 128 PDT (77.1%), which both provide 
lower light doses and lower local damage. 
 
Figures 3 and 4, which show the complete response rates at three months versus the effective 
light dose and the complete response rates at three months versus the local damage, support 
this assumption of no dependence. In fact, based on the near-zero slopes of the regression 
20 
 
lines (green curves in Figures 3 and 4), there are no associations of the complete response rate 
at three months with the effective light dose and local damage. 
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Figure 3: The complete response rates at three months reported in AK after one PDT session (column 8 in Table 1) versus the effective light dose 
(green bars in Figure 2). 
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Figure 4: The complete response rates at three months reported in AK after one PDT session (column 8 in Table 1) versus the local damage (red 
bars in Figure 2).
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IV. Discussion 
 
In this paper, ten ALA- and MAL-PDT protocols for PDT of AK are evaluated and compared 
using three metrics: the effective irradiance, the effective light dose and local damage. 
 
These protocols, which include protocols approved in Europe and the United States for 
treating AK (Table 1), were chosen based on the availability of spectral data necessary to 
compute the comparative metrics and for their published clinical efficacy. 
 
The effective irradiance obtained from the integration over the wavelength of the spectral 
irradiance weighted by the normalized absorption spectrum of PpIX (green curve in Figure 1) 
indicates the overall efficiency of the protocol for photoactivating PpIX. As described in the 
Results section, due to the position, shape and amplitude of the spectral irradiances, the 
protocol for daylight PDT on a clear sunny day and the PDT protocol for the Blu-U 
illuminator are the two most efficient protocols for photoactivating PpIX. By contrast, the 
protocol for the Ambulight PDT ™ and the PDT protocol for the PHOS-ISTOS device are the 
two least efficient protocols for photoactivating PpIX. The six remaining protocols are 
roughly equivalent to each other in terms of efficiency of photoactivation of PpIX. 
 
The effective light dose is obtained from the integration of the effective irradiance over the 
irradiation time and therefore represents the accumulation of the overall efficiency of the 
protocol for photoactivating PpIX over the irradiation time. As shown in Figure 2, the 
protocol for daylight PDT on a clear sunny day provides the highest effective light dose, 
36.56 J/cm
2
, approximately 3.8 times higher than the effective light doses achieved by the 
other investigated protocols. The protocols providing the four highest effective light doses are 
the protocols involving irradiation with daylight, white light or blue light, whereas the 
effective light doses for the protocols involving red light irradiation are much lower. These 
differences are explained by the generally much shorter irradiation times and poorer overlap 
with the normalized absorption spectrum of PpIX of the protocols involving red light 
irradiation compared to the other protocols, i.e., long wavelengths are characterized by low 
photo-activation intensities of PpIX (Table 1, Figure 1). 
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The local damage refers to the number of singlet oxygen molecules generated during the 
treatment in a 5 µm × 5 µm × 5 µm volume located at a depth of 100 µm in AK. This depth 
was chosen based on the 100-µm thickness for the epidermis reported in [55] and on the 
confinement of the AK to the epidermis. This number was estimated using an original 
mathematical model for PDT of AK that we published previously [7-9]. As shown in Figure 
2, four of the five highest levels of local damage are provided by the protocols involving 
irradiation with daylight, white light or blue light. With the exception of the protocol for the 
Ambulight PDT ™, the protocols involving red light irradiation, particularly the PDT 
protocol for the PHOS-ISTOS device, are the least efficient protocols in terms of local 
damage. Similar to the effective light dose, this result can be explained by the short irradiation 
times and the poor overlap with the normalized absorption spectrum of PpIX associated with 
these protocols. 
 
As discussed above, the protocols involving red light irradiation perform lower than the other 
protocols in terms of both the effective light dose and local damage. 
With regard to local damage, the 100-µm depth does not appear to be sufficient to highlight 
the deeper tissue penetration of red light compared to light of shorter wavelengths and to 
offset the poor overlap of the corresponding spectral irradiances with the normalized 
absorption spectrum of PpIX. Further studies involving a greater depth would be interesting to 
assess the impact of the deep tissue penetration of red light. 
 
In contrast to the effective light dose, local damage is computed by taking into account the 
spatial and temporal variations of the absorption spectrum of PpIX during irradiation. This 
distinction results in some slight differences in the rankings based on effective light dose and 
local damage. These differences can be explained in part by the incubation time, from which 
the absorption spectrum of PpIX is initialized. All four protocols involving an incubation time 
longer than four hours perform better in terms of effective light dose than in terms of local 
damage. The effective light dose therefore could be improved by including the incubation 
time in its calculation. 
 
Defined as quantities accumulating over the irradiation time, the effective light dose and local 
damage were expected to provide relevant trends for clinical efficacy. The complete response 
rate at three months, which was available for nine of the ten investigated protocols, was used 
to assess this clinical efficacy. As shown in Figures 3 and 4, there are no associations of the 
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complete response rate at three months with the effective light dose or local damage. Indeed, 
higher effective light doses or greater local damage does not always lead to higher complete 
response rates at three months. The effective light dose and local damage therefore cannot be 
used to determine the most efficient protocol in terms of the complete response rate at three 
months. 
 
This result could reflect the potential overtreatment of AK when using all protocols 
investigated in this study. This overtreatment would lead to effective light doses and local 
damage levels that are higher than the threshold values for PDT treatment success. Further 
investigations could be performed to determine whether such threshold values can be 
established. These investigations would extend the comparison to more protocols for PDT of 
AK, subject to published clinical efficacy and available spectral irradiance for the light 
source. Some emerging protocols aimed at allowing indoor daylight PDT [56] or maintaining 
pain control during the treatment [57] could be considered. However, this assumption of 
overtreatment should be further discussed as the complete response rates at three months were 
from different studies, and therefore their comparison is not fully reliable due to the 
variability across studies. 
Another hypothesis for explaining this result is potential deviations from the reported protocol 
information from which the effective light doses and local damage were computed. 
Information such as incubation time or irradiation time may not always be respected when 
treating patients, leading to biased complete response rates at three months. 
Given a protocol, the varying distances between the lesions and the light source result in inter-
patient/inter-lesion variability in the spectral irradiance. This variability is implicitly included 
in the complete response rate at three months but is not reflected by either the effective light 
dose or the local damage. This may also explain the absence of associations of the complete 
response rate at three months with the effective light dose or local damage. 
Regarding the local damage computation, the absorption spectrum of PpIX is initialized 
depending on the incubation time [7-9] and does not take into account the inter-patient/inter-
lesion variability in the conversion of MAL to PpIX. By contrast, the complete response rate 
at three months is intrinsically linked to this variability, which represents a source of bias in 
the comparisons of the complete response rate at three months with the effective light dose or 
local damage. 
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A limited, inaccurate, or incomplete understanding of the PDT process could also lead to 
biased local damage and potentially to the absence of associations between local damage and 
the complete response rate at three months. 
 
Consideration also needs to be given to the treatment-associated pain. With pain scores 
ranging from 0.4 to 1.9 (column 8 in Table 1), the protocol for daylight PDT, regardless of 
weather conditions, is described as a nearly painless treatment [16,18,21]. This description, 
which is also reported for the PDT protocol for a white LED lamp for operating rooms (pain 
score: 0.6), is applicable to the PDT protocol for the PHOS-ISTOS device (pain score: 0.6). 
Based on the pain score of 2 reported by Ibbotson et al [49] for the treatment of 61 non-
melanoma skin lesions, including only one AK, the protocol for the Ambulight PDT ™ 
involves little pain. By contrast, three of the protocols involving red light irradiation (the PDT 
protocol for the Waldmann PDT 1200L, the conventional protocol for Aktilite CL 128 PDT 
and the protocol for the Omnilux PDT ™) have pain scores higher than 5, indicating that 
these protocols are very painful. Severe pain and burning sensation of the skin, which may 
lead to interruption of treatment, have also commonly been reported for the PDT protocol for 
the CureLight 01 lamp [23,24,26] and for the PDT protocol for the Blu-U illuminator [38,39]. 
The protocols involving irradiation with daylight or white light and the protocols involving 
red light and low effective irradiances therefore seem to be more convenient for patients. 
Moreover, no associations seem to exist between the above-mentioned pain scores and 
adverse effects and the effective light doses or local damage. 
 
Since no single study provides complete response rates and pain scores for all ten protocols, 
data from various studies had to be pooled. To reduce variability across studies, only studies 
reporting complete response rates and pain scores achieved in AK after one PDT session are 
considered in the present study. Although reduced, variability still exists across studies, 
leading to limited reliability of the comparisons of complete response rates and pain scores. 
This constitutes a limitation of the study. To make the comparisons fully reliable, a single 
clinical study comparing the ten protocols should be conducted. 
 
Based on the above-discussed absence of an association between the effective light dose or 
local damage and the complete response rate at three months, protocols achieving high 
complete response rates at three months and low pain scores should be preferred, i.e., the 
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protocol for daylight PDT, regardless of weather conditions, and the PDT protocol for the 
PHOS-ISTOS device. 
 
V. Conclusions 
 
In this paper, we have compared ten efficient protocols for PDT of AK. This comparison in 
terms of effective irradiance, effective light dose and local damage demonstrates that the 
protocol for daylight PDT, regardless of weather conditions, the PDT protocol for a white 
LED lamp for operating rooms and the PDT protocol for the Blu-U illuminator perform better 
than the six other protocols, all of which involve red light illumination. However, no 
association between the effective light dose or local damage and the complete response rate at 
three months could be established. The protocol decision should therefore be determined 
based on the complete response rates and, in case of similar response rates, the pain scores. 
Based on the reported complete response rates at three months and pain scores, the protocol 
for daylight PDT, regardless of weather conditions, and the PDT protocol for the PHOS-
ISTOS device should be preferred. 
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